Home > Boards > US Listed > Biotechs > PDL BioPharma Inc. (PDLI)

7:07AM PDL BioPharma prices $260.87 mln aggregate principal

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
surf1944 Member Profile
 
Followed By 436
Posts 25,109
Boards Moderated 5
Alias Born 09/11/06
160x600 placeholder
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 1/15/2020 4:35:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/15/2020 12:34:01 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/10/2020 6:38:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/10/2020 6:37:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/10/2020 6:37:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/10/2020 6:36:50 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 1/9/2020 3:27:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/23/2019 8:00:01 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/19/2019 8:33:53 AM
PDL BioPharma Announces Upcoming Changes to its Board of Directors PR Newswire (US) - 12/19/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/16/2019 8:34:56 AM
PDL BioPharma Board of Directors Increases Share and Note Repurchase Authorization to $275 Million PR Newswire (US) - 12/16/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/13/2019 8:34:15 AM
PDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024 PR Newswire (US) - 12/13/2019 8:30:00 AM
SevenSaoi Capital Supportive of PDL BioPharma Announcement PR Newswire (US) - 12/10/2019 3:10:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/9/2019 8:04:56 AM
PDL BioPharma Announces Completion of Strategic Review Process PR Newswire (US) - 12/9/2019 8:00:00 AM
PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Ca... PR Newswire (US) - 12/3/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2019 6:03:21 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/14/2019 1:21:55 PM
PDL BioPharma Reaffirms Commitment To Shareholder Value Creation PR Newswire (US) - 11/14/2019 8:56:00 AM
Engine Capital Releases Presentation To Board Of PDL BioPharma PR Newswire (US) - 11/14/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/6/2019 4:16:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/6/2019 4:11:56 PM
PDL BioPharma Reports 2019 Third Quarter Financial Results PR Newswire (US) - 11/6/2019 4:05:00 PM
surf1944   Friday, 02/07/14 08:53:08 AM
Re: surf1944 post# 172
Post # of 207 
7:07AM PDL BioPharma prices $260.87 mln aggregate principal amount of its 4.00% Convertible Senior Notes due Feb 1, 2018 in an underwritten public offering (PDLI) 7.97 : The conversion rate of the Notes will initially be 109.1048 shares of common stock per $1,000 principal amount of the Notes equivalent to an initial conversion price of ~ $9.17 per share of common stock.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist